Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
QED Therapeutics
What AI says about QED Therapeutics
QED Therapeutics focuses on creating meaningful therapies for individuals with skeletal dysplasias, particularly achondroplasia and hypochondroplasia. They are currently involved in clinical trials to advance their investigational therapy, infigratinib.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Not in this profile yet:
Products & Services
Infigratinib
An investigational therapy for achondroplasia that has received breakthrough therapy designation from the FDA.
Clinical Trials
Programs such as the PROPEL Infant & Toddler trial and ACCEL observational study for children with achondroplasia and hypochondroplasia.
Common Questions
What is infigratinib?
Infigratinib is the first and only investigational therapy for achondroplasia awarded breakthrough therapy designation by the FDA.
Who can participate in the clinical trials?
Children with achondroplasia from birth to less than 3 years old can enroll in the PROPEL Infant & Toddler trial.
What conditions does QED Therapeutics focus on?
QED Therapeutics is dedicated to treating skeletal dysplasias, specifically achondroplasia and hypochondroplasia.